Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.185    -0.005 (-2.63%)
Bid:
0.18
Ask:
0.19
Spread: 0.01 (5.556%)
Market Cap: £1.37m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Interim Results

27 Sep 2005 12:09

Azure Holdings Plc (" Company") Interim results for the six months ended 30 June 2005 Chairman's statementIn the six months ended 30 June 2005 the Company incurred a loss before andafter taxation of ‚£74,000 (2004: ‚£229,000).Because of the lack of cash in the Company, creditors have increased butcontinue to be supportive.The directors are continuing to keep overheads to a minimum, the expenses beingthose necessary to maintain the Company's listing on AIM.The board continues to seek an acquisition for the Company.Owing to a technicality, the Company no longer has any authority to issue anyof its share capital and will therefore be convening an extraordinary generalmeeting for this purpose.Nicolas GreenstoneChairman27 September 2005Azure Holdings plcProfit and Loss Accountfor the six months ended 30 June 2005 6 months 6 months Year ended ended 30 ended 30 31 December June 2004 2004 June 2005 (unaudited) (audited) (unaudited) ‚£'000 ‚£'000 ‚£'000 Turnover - - - Administrative expenses (74) (229) (345) Operating loss (74) (229) (345) Loss on ordinary activities before (74) (229) (345)taxation Tax on loss on ordinary activities - - - Loss on ordinary activities after (74) (229) (345)taxation Retained loss for the period (74) (229) (345) Loss per ordinary share (0.15p) (0.65p) (0.86p) The profit and loss account has been prepared on the basis that all operationsare continuing operations. All recognised gains or losses are dealt withthrough the profit and loss account or statement of recognised gains andlosses.Azure Holdings plcBalance Sheetas at 30 June 2005 30 June 2005 30 June 31 December 2004 2004 (unaudited) (unaudited) (audited) ‚£'000 ‚£'000 ‚£'000 Current assets Debtors 3 14 7 Cash at bank and in hand 1 10 14 4 24 21 Creditors: amounts falling due within one (147) (81) (90)year Net current liabilities (143) (57) (69) Total assets less current liabilities (143) (57) (69) Net liabilities (143) (57) (69) Capital and reserves Called up Share Capital 5,475 5,371 5,475 Share Premium 10,279 10,279 10,279 Profit and loss account (15,897) (15,707) (15,823) Equity shareholders deficit (143) (57) (69) Azure Holdings plcCash Flow Statementfor the six months ended 30 June 2005 6 months ended 6 months ended 30 June 2005 30 June 2004 (unaudited) (unaudited) ‚£'000 ‚£'000 Net cash outflow from operating (13) (214)activities Financing Issue of ordinary shares - 105 Decrease in cash (13) (109)Azure Holdings plcNotes to the Interim Results 1. The interim results are unaudited and do not constitute statutory accounts within the meaning of section 240 of the Companies Act 1985. The figures for the year ended 31 December 2004 have been extracted from the statutory accounts filed with the registrar of companies on which the auditors gave an unqualified report. 2. The interim results have been prepared using the accounting policies set out in the statutory accounts for the year ended 31 December 2004. 3. The comparative figures for the unaudited interim results for the period ended 30 June 2004 are stated as announced on 29 September 2004. 4. Loss per share The earnings per share for the six months ended 30 June 2005 has beencalculated on the basis of the loss after taxation for the period of ‚£74,000(2004: ‚£229,000 ) and the weighted average number of shares in issue during theperiod of 48,317,569 (2004: 35,417,565). 5. The directors do not propose to pay a dividend for the period. 6. Copies of the interim results are available from the Company's registered office, One Great Cumberland Place, London, W1H 7AL. ENDAZURE HOLDINGS PLC
Date   Source Headline
15th Jan 202512:47 pmRNSHolding(s) in Company
15th Jan 202511:29 amRNSHolding(s) in Company
14th Jan 20257:00 amRNSHolding(s) in Company
9th Jan 202511:37 amRNSHolding(s) in Company
9th Jan 202511:14 amRNSHolding(s) in Company
8th Jan 20257:00 amRNSHolding(s) in Company
2nd Jan 202511:45 amRNSHolding(s) in Company
31st Dec 20241:06 pmRNSHolding(s) in Company
31st Dec 20248:39 amRNSUpdate on proposed sub-license of VAL201
30th Dec 20241:30 pmRNSResult of GM, Issue of Equity, Warrants and TVR
20th Dec 20247:00 amRNS-RValiRx launches new interactive investor website
10th Dec 20244:45 pmRNSBroker Offer Results & Director/PDMR Subscription
10th Dec 20243:03 pmRNSPosting of Circular and Notice of General Meeting
9th Dec 20247:00 amRNSConditional Fundraising & Launch of Broker Offer
22nd Nov 20247:00 amRNSInaphaea award of HEIF Funding and PhD sponsorship
20th Nov 20247:00 amRNSUpdate on proposed sub-license of VAL401
19th Nov 20247:00 amRNSContract Award
18th Nov 20247:00 amRNSFirst Sale of New Product Line
30th Oct 20247:00 amRNSUpdate on proposed sub-license of VAL201
18th Oct 20247:00 amRNSDirectorate Change
14th Oct 20247:00 amRNSInvestor Webinar
7th Oct 20247:00 amRNSInaphaea Co-Marketing Agreement
27th Sep 20247:00 amRNSHalf-year Report
26th Sep 20247:00 amRNSConclusion of Evaluation Project
24th Sep 20247:00 amRNSInaphaea Co-Marketing Agreement
18th Sep 20247:00 amRNSInaphaea Evaluation and Commercial Use Agreement
16th Sep 20247:00 amRNSInaphaea Co-Marketing Agreement
9th Sep 20247:00 amRNSInaphaea Evaluation and Commercial Use Agreement
9th Sep 20247:00 amRNSInvestor Evening
27th Aug 20247:00 amRNSInaphaea Evaluation and Commercial Use Agreement
12th Aug 20247:00 amRNSDirectorate Change
25th Jul 20247:00 amRNSDirectorate Changes
3rd Jul 20248:51 amRNSProposed Director Appointment
20th Jun 20245:56 pmRNSResult of AGM
19th Jun 202411:33 amRNSDirectorate Change
17th Jun 20247:00 amRNSInaphaea Contract Award
28th May 20247:00 amRNSInvestor Webinar
20th May 202412:00 pmRNSBusiness Update
16th May 20247:00 amRNSFurther re Final Results
15th May 20247:00 amRNSFinal Results and Notice of AGM
22nd Apr 20247:00 amRNSDirectorate Changes
21st Mar 20247:00 amRNSEvaluation Agreement with Imperial College London
19th Mar 20247:00 amRNSBoard Re-structuring and update on requisition
4th Mar 20245:47 pmRNSShareholder Requisition Notice
4th Mar 20247:00 amRNSProposed Appointment of Non-Executive Director
29th Feb 20242:00 pmRNSProposed Appointment of Non-Executive Director
13th Feb 20242:20 pmRNSFurther re Shareholder Requisition Notice
9th Feb 20245:06 pmRNSShareholder Requisition Notice
19th Jan 20247:00 amRNSChange of Broker
18th Jan 20247:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.